Galapagos NV (GLPG) and Adaptimmune (ADAP) Enter Collaboration Agreement Over uza-cel May 30, 2024 04:02PM
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential fut May 30, 2024 04:01PM
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future So May 30, 2024 04:01PM
BridGene Biosciences Announces Strategic Collaboration with Galapagos (GLPG) Jan 3, 2024 04:02PM
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets Jan 3, 2024 04:01PM
View Older Stories

Dec 19, 2023 04:01PM Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
Nov 6, 2023 07:45AM Galapagos NV (GLPG) and Landmark Bio Enter Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
Nov 6, 2023 07:45AM Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
May 5, 2023 04:01PM Galapagos creates new subscription right plans
Apr 26, 2023 04:01PM Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
Apr 25, 2023 04:01PM Galapagos NV (GLPG) Shareholders Approve All Board Proposals
Apr 25, 2023 04:01PM Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting
Mar 30, 2023 04:30PM Galapagos and NovAliX enter into an integrated drug discovery collaboration
Mar 23, 2023 04:01PM Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting
Mar 20, 2023 04:01PM Galapagos increases share capital through subscription right exercises
Feb 27, 2023 04:01PM Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Feb 23, 2023 04:01PM Galapagos announces full year 2022 results and outlook for 2023
Feb 9, 2023 04:01PM Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL
Feb 8, 2023 04:01PM Galapagos NV (GLPG) announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
Feb 8, 2023 04:01PM Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
Jan 10, 2023 04:01PM Galapagos receives transparency notification from FMR LLC
Jan 3, 2023 04:01PM Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference
Dec 23, 2022 04:01PM Galapagos receives transparency notification from FMR LLC
Dec 22, 2022 04:01PM Galapagos announces changes to Executive Committee
Dec 13, 2022 01:00AM Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
Nov 11, 2022 07:16AM Galapagos (GLPG) announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
Nov 11, 2022 07:15AM Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
Nov 8, 2022 04:01PM Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022
Nov 4, 2022 04:03PM Galapagos NV (GLPG) presents roadmap for pipeline and commercial growth at its R&D Day
Nov 4, 2022 04:01PM Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
Nov 3, 2022 04:01PM Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
Oct 17, 2022 01:30AM Galapagos to host its R&D Update 2022 in New York on 4 November 2022
Oct 6, 2022 04:01PM Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress
Oct 3, 2022 04:01PM Galapagos NV (GLPG) receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
Oct 3, 2022 04:01PM Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
Sep 27, 2022 04:01PM Galapagos increases share capital through subscription right exercises
Aug 29, 2022 04:01PM Galapagos receives transparency notification from FMR LLC
Aug 24, 2022 04:01PM Galapagos to present at upcoming investor conferences
Aug 18, 2022 04:01PM Galapagos receives transparency notification from FMR LLC
Aug 8, 2022 04:01PM Galapagos receives transparency notification from FMR LLC
Aug 4, 2022 04:01PM First key steps in pipeline rebuild and strong commercial progress in H1 2022
Jun 21, 2022 04:03PM Galapagos NV (GLPG) Acquires CellPoint and AboundBio
Jun 21, 2022 04:03PM Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
May 24, 2022 08:00AM Galapagos In-licenses Novel Drug Targets for Inflammatory Bowel Disease Discovered by Scipher Medicine’s Spectra™ Platform
Aug 19, 2020 06:10AM Gilead Sciences (GILD) Receives CRL for Filgotinib for Treatment of Moderately to Severely Active Rheumatoid Arthritis
Aug 12, 2020 04:01PM Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease
Nov 21, 2019 08:00AM Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors
Nov 9, 2019 04:30PM New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile
Nov 9, 2019 04:30PM NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE
Oct 31, 2019 04:46PM Gilead Sciences (GILD), Galapagos (GLPG) to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting
Oct 31, 2019 04:01PM Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting
Aug 23, 2019 04:01PM Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
Aug 15, 2019 04:02PM UPDATE: Gilead Sciences (GILD), Galapagos NV (GLPG) Report EMA Validates Marketing Application for Filgotinib for Treatment of Rheumatoid Arthritis
Aug 15, 2019 04:01PM European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
Feb 7, 2019 01:31AM Evotec and Galapagos enter into collaboration in the field of fibrosis
View Older Stories